glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carton, Rx Only… recall
FDA recall D-0202-2025 · initiated Dec 17, 2024
Amerisource Health Services LLC recalled glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carto… in Dec 2024 — an FDA Class II recall (D-0202-2025) because Failed Dissolution Specifications:.
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Failed Dissolution Specifications:
Wrong strength, or it did not keep
The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.
This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.
Is your product affected? Check the lot number
A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.
Quantity recalled: 2,028 units (cartons of 30 individual unit doses)
Details
- Product
- glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC: 60687-480-21, Unit Dose NDC: 60687-480-11
- Recalling company
- Amerisource Health Services LLC
- Classification
- Class II
- Status
- Terminated
- Type
- Voluntary: Firm initiated
- Distribution
- Nationwide in the USA
- Initiated
- Dec 17, 2024
- FDA report date
- Jan 22, 2025
Frequently asked
- Was glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carto… recalled?
- Amerisource Health Services LLC recalled glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carto… in Dec 2024 — an FDA Class II recall (D-0202-2025) because Failed Dissolution Specifications:. May cause temporary or medically reversible harm; low probability of serious harm.
- Why was glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carto… recalled?
- Per the FDA enforcement record, the reason for recall D-0202-2025 was: Failed Dissolution Specifications:
- Is a recalled glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carto… dangerous to take?
- An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
- Which lots of glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carto… are affected?
- Distributed: Nationwide in the USA. The recall covers these lots — Lot # 1012910, Exp Date: 04/30/2025. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0202-2025.